Biogen Posts Adj. Profit In Q4; Sees FY22 Results Below Market

Biogen Inc. (BIIB) reported that its fourth quarter non-GAAP earnings per share was $3.39 compared to a loss of $1.05, prior year. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $3.38, for the quarter. Analysts' estimates typically exclude special items.

Net income attributable to Biogen Inc. was $368.2 million or $2.50 per share compared to $357.9 million or $2.32 per share, previous year.

Total revenue declined to $2.73 billion from $2.85 billion, prior year. Analysts on average had estimated $2.62 billion in revenue.

For 2022, Biogen expects: non-GAAP EPS to be between $14.25 and $16.00; and revenue to be between $9.7 billion and $10.0 billion. Analysts expect the company to report profit per share of $18.85 on revenue of $10.34 billion. The company noted that its financial guidance assumes minimal ADUHELM revenue in 2022.

Shares of Biogen Inc. were down nearly 4% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT